Search This Blog

Wednesday, November 1, 2023

Nurix: Partial Clinical Hold For NX-2127 Phase 1 Trial

 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. Screening and enrollment of new study participants has been paused. Patients currently enrolled in the clinical study who are deriving clinical benefit may continue to receive treatment in accordance with the ongoing study protocol. Nurix is working with the FDA to resolve the partial clinical hold as soon as possible.

The partial clinical hold follows the company’s communication to the FDA of its intention to transition to an improved manufacturing process. Nurix’s other drug programs are not affected by the NX-2127 manufacturing process improvement.

https://www.globenewswire.com/news-release/2023/11/01/2771669/0/en/Nurix-Therapeutics-Announces-Partial-Clinical-Hold-For-NX-2127-Phase-1-Trial.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.